Article
Effects of mutagenic and chain-terminating nucleotide analogs on enzymes isolated from hepatitis C virus strains of various genotypes.
Antimicrobial agents and chemotherapy - 1 Jun 2008
Heck Julie A, Lam Angela M I, Narayanan Nirupama, Frick David N
Abstract excerpt
The development of effective therapies for hepatitis C virus (HCV) must take into account genetic variation among HCV strains. Response rates to interferon-based treatments, including the current preferred treatment of pegylated alpha interferon administered with ribavirin, are genotype specific. Of the numerous HCV inhibitors currently in development as antiviral drugs, nucleoside analogs that target the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
